Drugs / INCB123667
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07559396 | May 2026 → Jan 2027 expected | impaired renal function disease | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT07559474 | May 2026 → Apr 2027 expected | liver disorder | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT07218744 | Nov → Dec 2025 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06909162 | May 2025 → May 2026 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07023627 | Nov 2025 → Apr 2027 expected | ovarian cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07214779 | Dec 2025 → Nov 2028 expected | ovarian cancer | Incyte Corporation | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-14 | Incyte Corporation | Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer incyte.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB123667 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07214779 ↗ |
| Route | Oral | “single dose administered orally” NCT06909162 ↗ |